Riskpilot← Back to searchSign inGet full accessAsarina Pharma ApS
APSIn liquidationCVR 38495712Prinsesse Alexandrines Alle 12, 3. tvResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20171 employeeswww.asarinapharma.com
Revenue 2024
DKK -365K
-59% vs 2023
EBITDA margin
334.7%
+83% vs 2023
Equity ratio
-6.7%
Financial strength
Net profit 2024
DKK -1,3M
+97% vs 2023
| Revenue | DKK -365K | -59% |
| EBITDA | DKK -1,2M | +83% |
| Net profit | DKK -1,3M | +97% |
| Total assets | DKK 1,6M | -36% |
| Equity | DKK -107K | -109% |
| Employees | 1 | — |
Legal name
Asarina Pharma ApS
CVR number
38495712
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
16. marts 2017
Share capital
DKK 50.000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en likvidator
Company purpose
Selskabet har til formål at gennemføre forsknings- og udviklingsaktiviteter relateret til udvikling af lægemidler, herunder særligt lægemidler til behandling af præmenstruel dysfori (PMDD), og at udføre aktiviteter, som efter bestyrelsens skøn er naturligt relaterede hertil.
Address
Prinsesse Alexandrines Alle 12, 3. tv
Phone
+4551323698
Email
jakob.dynnes@asarinapharma.com
Website
www.asarinapharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -1.181 | -891.919 | -1.446 | -1.891 | -887 | -509 | -884 | -365 |
| Staff expenses | -1.603 | -2.457.910 | -5.124 | -5.268 | -3.310 | -1.926 | -2.461 | -457 |
| EBITDA | -16.124 | -32.209.631 | -51.648 | -52.206 | -25.255 | -6.609 | -7.043 | -1.223 |
| Depreciation & amort. | -3.145 | -3.973.000 | -3.974 | -4.036 | -4.257 | -4.257 | -37.064 | -284 |
| EBIT | -19.269 | -36.182.631 | -55.622 | -56.242 | -29.513 | -10.866 | -44.107 | -1.507 |
| Net financials | -218 | -596.709 | -2.265 | -786 | -60 | -31 | 28 | -28 |
| Profit before tax | -19.487 | -36.779.340 | -57.887 | -57.028 | -29.572 | -10.897 | -44.079 | -1.535 |
| Tax | -3.111 | -5.500.000 | -5.500 | -5.500 | -4.868 | -1.074 | -1.176 | -202 |
| Net profit | -16.376 | -31.279.340 | -52.387 | -51.528 | -24.705 | -9.823 | -42.903 | -1.333 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 63.731 | 59.471.888 | 63.760 | 61.607 | 50.679 | 43.649 | 2.490 | 1.601 |
| Equity | 43.342 | 12.062.389 | 51.052 | 44.077 | 48.991 | 42.709 | 1.226 | -107 |
| Long-term debt | 18.737 | 40.320.829 | 0 | 8.316 | 0 | 0 | 0 | 0 |
| Short-term debt | 1.652 | 7.088.670 | 12.708 | 9.214 | 1.688 | 941 | 1.265 | 1.708 |
| Total debt | 20.389 | 47.409.499 | 12.708 | 17.530 | 1.688 | 941 | 1.265 | 1.708 |
EBITDA margin
-122306300.0%
This company
15.8%
Market median
-774090606% vs market
20172024
Equity ratio
-6.7%
This company
38.2%
Market median
-118% vs market
20172024
Return on equity
-133323200.0%
This company
18.4%
Market median
-724582709% vs market
20172024
Net profit margin
-133323200.0%
This company
8.1%
Market median
-1645965532% vs market
20172024
Asset turnover
-0.23×
This company
1.12×
Market median
-121% vs market
20172024
Debt / equity
15.92×
This company
0.62×
Market median
-2468% vs market
20172024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-03-16 – 2017-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PH Chief Executive Officer | Chief Executive Officer | 2017 | — | — |
JD Unofficial title | Unofficial title | 2025 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2017 | — | — | |
| Board of Directors | 2017 | — | — | |
| Chairman | 2018 | — | — | |
| Chairman | 2017 | — | — | |
| Board of Directors | 2017 | — | — | |
| Board of Directors | 2017 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2017 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Asarina Pharma ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Peter Hviid Nordkild | Chief Executive Officer | 0 companies |
| Jakob Dynnes Hansen | Unofficial title | 0 companies |
| Miroslav Reljanovic | Board of Directors | 0 companies |
| Claude Thierry Laugel | Board of Directors | 0 companies |
| Paul Karl Mikael de Potocki | Chairman | 0 companies |
| Ola Gösta Flink | Chairman | 0 companies |
| Erik Graham Fagg | Board of Directors | 0 companies |
| Sten Gunnar Otto Skolling | Board of Directors | 0 companies |